Abstract 【Objective】 This study aimed to access the efficacy and safety of the medication use of long-acting β2-agonist combined with long-acting muscarinic antagonist (LABA/LAMA) for symptomatic COPD patients in the real world. 【Methods】 Patients were enrolled in the study cohort if they were diagnosed as COPD with CAT≥10 scores and new to LAMA/LABA treatment from the Second Xiangya Hospital of Central South University and Zhuzhou Central Hospital during December 2018 and January 2021.Patients enrolled in the study treated with LABA/LAMA 3 for months. According to whether other maintenance medication was used before enrollment, they were divided into 4 groups: the initial group, prior LAMA group,prior ICS/LABA group,prior ICS/LABA plus LAMA group. The effectiveness outcome was the change of CAT scores, the occurrence of moderate to severe acute exacerbations and clinical control during follow-up. Safety outcome was the appearance of adverse effects. 【Results】 Overall study population and patients from the initial group, prior LAMA group, prior ICS/LABA group ameliorated significantly in CAT scores (P<0.05), After 3 months, LABA/LAMA significantly reduced the rate of moderate or severe exacerbations(P<0.05). Study showed a significant improvement in clinical control (P<0.05). The overall incidence of adverse events is low. 【Conclusion】 Patients with COPD symptoms benefit from LABA/LAMA by improving their clinical symptoms, reducing the rate of moderate or severe exacerbations and improving clinical control rates. LABA/LAMA is safe and well tolerated.
[1] 陈亚红.2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J].中国医学前沿杂志(电子版),2019,11(1):1-14.
[2] MALERBA M,FOCI V,PATRUCCO F,et al,Single inhaler LABA/LAMA for COPD[J].Front Pharmacol,2019,10:390.
[3] 柳涛,蔡柏蔷. 一种新型的生活质量评估问卷:慢性阻塞性肺疾病评估测试[J].中国医学科学院学报,2010,32(2):234-238.
[4] 王天立,杨泽刚,裴文军.CAT评分在稳定期COPD患者病情评估中的价值[J].医学临床研究,2013,30(6):1229-1230.
[5] KON S, CANAVAN J, JONES S, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis[J].Lancet Respir Med,2014,2(3):195-203.
[6] SOLER-CATALUÑA J J, ALMAGRO P, HUERTA A, et al. Clinical control criteria to determine disease control in patients with severe COPD: The clave study[J].Int J Chron Obstruct Pulmon Dis,2021,16:137-146.
[7] DING B, SMALL M, BERGSTRÖM G,et al. COPD symptom burden: impact on health care resource utilization, and work and activity impairment[J].Int J Chron Obstruct Pulmon Dis,2017,12:677-689.
[8] 陈平. 长效β2-受体激动剂与长效抗胆碱能药物联合治疗慢性阻塞性肺疾病的疗效[J].中华结核和呼吸杂志,2014,12:951-953.
[9] LIPSON D A, BARNHART F, BREALEY N,et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD[J].N Engl J Med,2018,378(18):1671-1680.
[10] WORTH H, BUHL R, CRIÉE C P, et al.GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study[J].Respir Med,2017,131:77-84.
2022, Vol. 39 
